Viking Therapeutics - Press Releases http://ir.vikingtherapeutics.com/ Viking Therapeutics Announces VK5211 Phase 2 Study Results Selected for Plenary Oral Presentation at ASBMR 2018 Annual Meeting http://ir.vikingtherapeutics.com/2018-07-17-Viking-Therapeutics-Announces-VK5211-Phase-2-Study-Results-Selected-for-Plenary-Oral-Presentation-at-ASBMR-2018-Annual-Meeting Presentation to Highlight Data for Novel, Orally Available SARM in Patients Recovering from Hip Fracture Surgery Tue, 17 Jul 2018 07:05:00 -0400 http://ir.vikingtherapeutics.com/2018-07-17-Viking-Therapeutics-Announces-VK5211-Phase-2-Study-Results-Selected-for-Plenary-Oral-Presentation-at-ASBMR-2018-Annual-Meeting Viking Therapeutics Announces Closing of Public Offering of Common Stock http://ir.vikingtherapeutics.com/2018-06-12-Viking-Therapeutics-Announces-Closing-of-Public-Offering-of-Common-Stock Tue, 12 Jun 2018 07:05:00 -0400 http://ir.vikingtherapeutics.com/2018-06-12-Viking-Therapeutics-Announces-Closing-of-Public-Offering-of-Common-Stock Viking Therapeutics Announces Pricing of $67.5 Million Public Offering of Common Stock http://ir.vikingtherapeutics.com/2018-06-07-Viking-Therapeutics-Announces-Pricing-of-67-5-Million-Public-Offering-of-Common-Stock Thu, 07 Jun 2018 08:30:00 -0400 http://ir.vikingtherapeutics.com/2018-06-07-Viking-Therapeutics-Announces-Pricing-of-67-5-Million-Public-Offering-of-Common-Stock Viking Therapeutics Announces Proposed Public Offering of Common Stock http://ir.vikingtherapeutics.com/2018-06-06-Viking-Therapeutics-Announces-Proposed-Public-Offering-of-Common-Stock Wed, 06 Jun 2018 16:01:00 -0400 http://ir.vikingtherapeutics.com/2018-06-06-Viking-Therapeutics-Announces-Proposed-Public-Offering-of-Common-Stock Viking Therapeutics Completes Enrollment in Phase 2 Study of VK2809 in Patients with Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease http://ir.vikingtherapeutics.com/2018-06-05-Viking-Therapeutics-Completes-Enrollment-in-Phase-2-Study-of-VK2809-in-Patients-with-Hypercholesterolemia-and-Non-Alcoholic-Fatty-Liver-Disease Top-Line Results Expected in Second Half of 2018 Tue, 05 Jun 2018 07:01:00 -0400 http://ir.vikingtherapeutics.com/2018-06-05-Viking-Therapeutics-Completes-Enrollment-in-Phase-2-Study-of-VK2809-in-Patients-with-Hypercholesterolemia-and-Non-Alcoholic-Fatty-Liver-Disease